SYRE
Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) has 16 SEC Form 4 filings (51 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Jul 3, 2026.
The most active filer is Chief Financial Officer Burrows Scott L with 5 filings. Insiders have net sold $422.9M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Cameron Turtle
- Employees:73
- HQ:Waltham, MA, US
- IPO:2016-04-07
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$422.9M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$8.9B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Financial Officer | Sale | 7,500 | $658K | Jul 3 | SEC ↗ | |
| Chief Medical Officer | Sale | 8,334 | $731K | Jul 3 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.3M | Jul 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 15,000 | $1.3M | Jun 27 | SEC ↗ | |
Fairmount Funds Management LLCFirst filing | Director | Sale | 4,684,781 | $399.7M | Jun 24 | SEC ↗ |
| Director | Sale | 20,000 | $2.0M | Jun 24 | SEC ↗ | |
| Chief Medical Officer | Sale | 8,333 | $625K | Jun 4 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.1M | Jun 4 | SEC ↗ | |
| Chief Financial Officer | Sale | 7,500 | $533K | Jun 4 | SEC ↗ | |
HENDERSON MICHAEL THOMASFirst filing | Director | Sale | 80,000 | $6.0M | May 9 | SEC ↗ |
| Chief Financial Officer | Sale | 12,500 | $892K | May 2 | SEC ↗ | |
| Chief Medical Officer | Sale | 78,333 | $5.6M | May 2 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.1M | May 2 | SEC ↗ | |
Turtle CameronFirst filing | Chief Executive Officer | Sale | 15,000 | $740K | Apr 3 | SEC ↗ |
Sloan SheldonFirst filing | Chief Medical Officer | Sale | 7,958 | $398K | Apr 3 | SEC ↗ |
Burrows Scott LFirst filing | Chief Financial Officer | Sale | 7,500 | $370K | Apr 3 | SEC ↗ |
Related companies
Spyre Therapeutics, Inc. is in the Healthcare sector.